Abstracts

Epidemiologic Benefits and Cost-Effectiveness of Improving Rwanda’s HIV Care Cascade

Background: Connecting HIV+ individuals to treatment programs and sustaining effective antiretroviral therapy (ART) is a challenge in developing countries. The implications of addressing patient linkage and retention are not only partially characterized. We use the national coverage of data on HIV care in Rwanda to estimate the epidemiologic benefits and cost-effectiveness of improving the HIV…

The Cost-Effectiveness of CD4 Cell Count Versus HIV RNA Viral Load for ART Initiation

Background: The UNAIDS has proposed achieving 90% diagnosis of HIV-positive persons, 90% antiretroviral therapy (ART) coverage among those diagnosed, and 90% viral suppression among those on ART. ART initiation guidelines have primarily depended on CD4 cell count, with the World Health Organization (WHO) currently recommending ART initiation for persons with CD4≤500 cells/µL. However, HIV transmission,…

Acute HIV Infection Transmission Among People Who Inject Drugs in an Established Epidemic Setting.

Background: Among people who inject drugs (PWID), little is known about the contribution of acute HIV infection (AHI) to incident infections. Understanding its role in overall transmission may be crucial to improving the effectiveness of prevention strategies. We constructed an agent-based model (ABM) to estimate the proportion of transmission events attributable to AHI within an…

Predicted Impact of Antiretroviral Treatment on Preventing New HIV Infections in 53 Low- and Middle-Income Countries With Large HIV Epidemics

Background: Clinical trials and observational studies have demonstrated that antiretroviral treatment can reduce the risk of HIV transmission. However, many countries still have low rates of antiretroviral treatment uptake. Methods: Standardised epidemiological data were compiled from 36 African and 17 non-African low- and middle-income countries with least 40,000 HIV-infected people. Estimates of new HIV infections…

A Predictive Risk Model for First-Line Treatment Failure in South Africa

Background: Although individual predictors of first line antiretroviral therapy (ART) failure have been identified, few studies in resource-limited settings have been large enough for predictive modeling. Understanding the absolute risk of first line failure is useful for patient monitoring and for effectively targeting limited resources for second line ART. The aims of this study are…

U.S. Population Benefits of HIV Preexposure Prophylaxis for Injection Drug Users

Background: A Centers for Disease Control and Prevention (CDC)-sponsored randomized trial of daily oral preexposure chemoprophylaxis (PrEP) with Truvada demonstrated efficacy in preventing HIV infection among injection drug users (IDUs) in Thailand. CDC recommends PrEP for men who have sex with men (MSM) based on its effectiveness and cost-effectiveness. CDC also recommends considering PrEP for…

Procreation in HIV-Serodiscordant Couples: TasP, PrEP, or Assisted Reproduction?

Background: In the U.S., 2014 CDC guidelines based on expert recommendations have for the first time recommended PrEP as one of several options for fertile HIV-uninfected female/HIV-1-infected male couples on combination antiretroviral therapy (cART) with plasma HIV RNA <50 copies/mL desiring a child. However, in other Northern countries, medically assisted procreation (MAP) is still the…